4-(3-Methylhexan-3-yl)pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(3-Methylhexan-3-yl)pyrimidine
• 英文别名: 4-(3-methylhexan-3-yl)pyrimidine
• 化学式: C₁₁H₁₈N₂
• 分子量: 178.27
• InChiKey: RTYQZKXKXOYGSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS
  申请人：Sanofi

  公开号：US20140243292A1

  公开（公告）日：2014-08-28

  The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的取代2-(色烯-6-氧基)-噻唑，其中Ar，R2，R3和R4如权利要求所定义。公式I化合物是钠钙交换器（NCX）的抑制剂，特别是钠钙交换器亚型1（NCX1）的抑制剂，并适用于治疗细胞内钙离子稳态受到干扰的多种疾病，如心律失常，心力衰竭和中风。本发明还涉及制备公式I化合物的方法，它们作为药物的用途，以及包含它们的制药组合物。
• Compounds and compositions as inhibitors of MEK
  申请人：NOVARTIS AG

  公开号：US10011599B2

  公开（公告）日：2018-07-03

  The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.

  本发明涉及式 I 的化合物： 其中 n、R1、R2、R3a、R4 和 R5 在发明概述中定义；能够抑制 MEK 的活性。本发明进一步提供了制备本发明化合物的工艺、包含此类化合物的药物制剂以及使用此类化合物和组合物治疗癌症等过度增殖性疾病的方法。
• Compositions and methods for treating parasitic diseases
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US11208411B2

  公开（公告）日：2021-12-28

  Disclosed herein, inter alia, are compositions and methods for treating parasitic diseases.

  本文特别披露了治疗寄生虫病的组合物和方法。
• Heteroaryl compounds and methods of use thereof
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US11332462B2

  公开（公告）日：2022-05-17

  Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

  本文提供了噻吩化合物、其合成方法、包含这些化合物的药物组合物及其使用方法。本文提供的化合物可用于治疗、预防和/或控制各种神经系统疾病，包括但不限于精神病和精神分裂症。
• BIARYL KINASE INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20170183340A1

  公开（公告）日：2017-06-29

  The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.